Brentuximab Vedotin May Improve Overall Survival in Patients With Hodgkin Lymphoma
July 15, 2022
July 15, 2022
ROCHESTER, Minnesota, July 15 (TNSjou) -- The Mayo Clinic issued the following news release on July 14, 2022:
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Socie . . .
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Socie . . .